AU2005324199A1 - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine Download PDF

Info

Publication number
AU2005324199A1
AU2005324199A1 AU2005324199A AU2005324199A AU2005324199A1 AU 2005324199 A1 AU2005324199 A1 AU 2005324199A1 AU 2005324199 A AU2005324199 A AU 2005324199A AU 2005324199 A AU2005324199 A AU 2005324199A AU 2005324199 A1 AU2005324199 A1 AU 2005324199A1
Authority
AU
Australia
Prior art keywords
effective
concentrations
prevention
combinations
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005324199A
Inventor
Magd Ahmed Kotb Abdalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2005324199A1 publication Critical patent/AU2005324199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

WO 2006/072259 PCT/EG2005/000044 1 Taurine synthesis, production and utility as a medicine Technical Field: 1. Medicine Background Art: The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Disclosure of Invention: Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions. Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins. Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. Taurine is also effective in gall stone dissolution. Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins. Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases.
WO 2006/072259 PCT/EG2005/000044 2 The Novel Idea: To control: blood levels of lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution, the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins. Detailed Description of the Requested Patent: a. Taurine manufactured by all known ways as sulphonation of ethyl alcohol followed by substitution reaction at C2 or recombinant DNA technology to produce 2 aminoethyl sulphonic acid or any possible way, or by the use probiotics to promote the use of intestinal bacterial flora to reclaim taurine from the previously liver formed taurocholic acid and taurochenodexoycholic acid etc.... b. Acetyl cysteine is manufactured by all known ways. c. Water soluble vitamins are manufactured by all known ways. Where: i. All " a" "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or "a+c"; or "b+c" or, "a+ b+ c". ii. All " a" "b" and "c" are effective if given as 'a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, or topical preparations. iii. All and any composition and any and all concentrations of ''a'', or "b" or "'c"5 or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" are effective. iv. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, or forms.
WO 2006/072259 PCT/EG2005/000044 3 v. The "a", or "b" or 4c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling asthersclerosis and cardiac diseases. vi. The "a", or "b" or "c"' or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders. vii. The "a", or "b" or "c" or as "a+b", or "'a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology. ix. The "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases. x. The "a", or "b" or "c"5 or as "a+b", or "a+c", or "b+c or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.

Claims (10)

1. All "a", "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c".
2. All "a", "b" and "c" are effective if given as "a", or "b" or "'c"l or as "a+b" , or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, topical preparations.
3. All and any composition and any and all concentrations of "a", or "b" or "'c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" are effective.
4. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, forms or shapes.
5. The "a", or "b" or "'c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling astherselerosis and cardiac diseases. WO 2006/072259 PCT/EG2005/000044 5
6. The "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
7. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are .effective in prevention and controlling cholestasis disorders of any aetiology.
8. The "a", or "b" or 6c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
9. The "a", or "b" or 4c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling gall stone diseases.
10. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.
AU2005324199A 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine Abandoned AU2005324199A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
EG2005010013 2005-01-05
PCT/EG2005/000044 WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Publications (1)

Publication Number Publication Date
AU2005324199A1 true AU2005324199A1 (en) 2006-07-13

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005324199A Abandoned AU2005324199A1 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (en)
JP (1) JP2008526789A (en)
KR (1) KR20070091198A (en)
CN (1) CN101146767A (en)
AP (1) AP2007004084A0 (en)
AU (1) AU2005324199A1 (en)
BR (1) BRPI0519606A2 (en)
CA (1) CA2593563A1 (en)
EA (1) EA200701434A1 (en)
IL (1) IL184221A0 (en)
MA (1) MA29238B1 (en)
MX (1) MX2007008196A (en)
NO (1) NO20074937A (en)
TN (1) TNSN07226A1 (en)
WO (1) WO2006072259A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091219A (en) 2007-11-30 2010-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (en) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 Preparation method for taurine
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (en) * 1981-12-22 1983-08-19 Junichi Azuma Remedy for cardiac insufficiency
JPH08208464A (en) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd Agent for treatment and prevention of hyperlipemia
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1268733C (en) * 2004-07-20 2006-08-09 刘辉 Taurine functional beer and its producing process

Also Published As

Publication number Publication date
MX2007008196A (en) 2008-02-22
TNSN07226A1 (en) 2008-11-21
IL184221A0 (en) 2008-12-29
AP2007004084A0 (en) 2007-08-31
CN101146767A (en) 2008-03-19
WO2006072259A2 (en) 2006-07-13
MA29238B1 (en) 2008-02-01
WO2006072259A3 (en) 2007-10-04
EP1844006A2 (en) 2007-10-17
CA2593563A1 (en) 2006-07-13
KR20070091198A (en) 2007-09-07
JP2008526789A (en) 2008-07-24
EA200701434A1 (en) 2008-10-30
NO20074937A (en) 2007-09-28
BRPI0519606A2 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
EP0291245B1 (en) Benzoylaminophenoxybutanoic acid derivatives
JP2008013578A (en) Cosmetic composition
EP0951909B1 (en) Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof
KR20120084718A (en) Collagen production accelerating composition
ITRM930399A1 (en) USE OF L-CARNITINE ESTERS OR ACIL L-CARNITINE WITH HYDROXIACID TO PRODUCE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES.
AU2005324199A1 (en) Taurine synthesis, production and utility as a medicine
JP5671483B2 (en) Pigmentation preventing or improving agent
WO2011074643A1 (en) Prophylactic or ameliorating agent fo pigmentation
JP3884581B2 (en) Acne preventive / ameliorating agent
JP7073384B2 (en) Compounds and usage
CN1466453A (en) Fatty acid analogues for the treatment of proliferative skin disorders
US6451761B1 (en) N′N′-dichlorinated omega-amino acids and uses thereof
JP4226324B2 (en) Carboxylic acid type lipid
FR2989087A1 (en) NOVEL OLIGOSACCHARIDE COMPOUNDS AND THEIR COSMETIC USE
HU229161B1 (en) Lipophilic diesters of chelating agents
WO2011030727A1 (en) External preparation containing pantethine phosphate ester
AU2011337596B2 (en) Novel compound and medical use thereof
US20090203654A1 (en) Cosmetic and pharmaceutical compositions
EP1234816A1 (en) Scyphostatin analogues as SMase inhibitors
WO2006048430A1 (en) SALTS OF N-ACYL-L-ASPARTATE-β-MONOESTER AND/OR OF N-ACYL-L-GLUTAMATE-Ϝ-MONOESTER, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN THERAPEUTIC OR COSMETIC COMPOSITIONS
WO2013068964A1 (en) Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations
JP2013001659A (en) Skin care preparation
EP4296259A1 (en) Novel ceramide, preparation method therefor, and use thereof
KR20030003952A (en) Compositions for the prevention and treatment of inflammatory skin diseases
US10745349B2 (en) Ceramide dimer, method for the production thereof, and use of same

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application